PDGFRA公司
癌症研究
生物
荧光原位杂交
肺癌
染色体
伊马替尼
分子生物学
病理
遗传学
主旨
医学
间质细胞
基因
髓系白血病
作者
Alex H. Ramos,Amit Dutt,Craig H. Mermel,Sven Perner,Jeonghee Cho,Christopher J. Lafargue,Laura A. Johnson,Ann-Cathrin Stiedl,Kumiko Tanaka,Adam J. Bass,Jordi Barretina,Barbara A. Weir,Rameen Beroukhim,Roman K. Thomas,John D. Minna,Lucian R. Chirieac,Neal I. Lindeman,Thomas J. Giordano,David G. Beer,Patrick Wagner
标识
DOI:10.4161/cbt.8.21.9764
摘要
In cancer, proto-oncogenes are often altered by genomic amplification. Here we report recurrent focal amplifications of chromosomal segment 4q12 overlapping the proto-oncogenes PDGFRA and KIT in non-small cell lung cancer (NSCLC). Single nucleotide polymorphism (SNP) array and fluorescent in situ hybridization (FISH) analysis indicate that 4q12 is amplified in 3-7% of lung adenocarcinomas and 8-10% of lung squamous cell carcinomas. In addition, we demonstrate that the NSCLC cell line NCI-H1703 exhibits focal amplification of PDGFRA and is dependent on PDGFRalpha activity for cell growth. Treatment of NCI-H1703 cells with PDGFRA-specific shRNAs or with the PDGFRalpha/KIT small molecule inhibitors imatinib or sunitinib leads to cell growth inhibition. However, these observations do not extend to NSCLC cell lines with lower-amplitude and broader gains of chromosome 4q. Together these observations implicate PDGFRA and KIT as potential oncogenes in NSCLC, but further study is needed to define the specific characteristics of those tumors that could respond to PDGFRalpha/KIT inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI